New WuXi/Lilly Deal Builds On Long Partnership
This article was originally published in PharmAsia News
WuXi and Lilly are building on a long history of collaboration by entering into a new partnership for the development in China of an experimental drug that addresses cardiovascular risk in patients with dyslipidemia, a huge unmet medical need in the country. The move also marks another step in WuXi’s flexible approach to international alliances.
Register for our free email digests: